SCHEMBL6506768

SCHEMBL6506768

CON=C(C)C(C)(Cc1ccc(O)cc1)C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.42
BLM P54132 1/20 0.42
ESR2 Q92731 5/20 0.39
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.36
F13A1 P00488 1/20 0.36
PTPRB P23467 2/20 0.36
MMP8 P22894 1/20 0.36
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
MIF P14174 1/20 0.35
CA12 O43570 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
PTPN1 P18031 2/20 0.34
ESRRG P62508 1/20 0.34
PTPN2 P17706 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6506766 1.00 ESR1 (0.42) ESR1BLMESR2MEN1TSHR
SCHEMBL6507108 0.88 MMP8 (0.39) ESR1BLMESR2MEN1TSHR
SCHEMBL6507111 0.88 MMP8 (0.39) ESR1BLMESR2MEN1TSHR
SCHEMBL6509010 0.85 ESR1 (0.40) ESR1BLMESR2MEN1TSHR
SCHEMBL6501851 0.84 MMP8 (0.42) BLMMEN1KMT2APTPRBMMP8
SCHEMBL6501855 0.84 MMP8 (0.42) BLMMEN1KMT2APTPRBMMP8
SCHEMBL6514361 0.83 ESR1 (0.48) ESR1BLMESR2MEN1TSHR
SCHEMBL3665931 0.75 ESR1 (0.53) ESR1BLMESR2MEN1TSHR
SCHEMBL9285117 0.72 BLM (0.53) ESR1BLMESR2MEN1TSHR
SCHEMBL503526 0.72 BLM (0.67) ESR1BLMESR2MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245512-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails ULRICH PETER C 2005-11-03 US disclosed
WO-2005040127-A1 NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME LG LIFE SCIENCES LTD. (KR) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245512-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails TERT, TELO2, HKDC1 ESR1 2538/4885BLM 2150/4885ESR2 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.